Transforming viral vector manufacturing with next-generation CGMP plasmids platform

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Transforming viral vector manufacturing with next-generation CGMP plasmids platform

Next-generation CGMP plasmid production platforms can deliver tangible benefits for viral vector manufacturing, helping to enhance efficiency, reduce costs, and improve scalability. This webinar will share key innovations in plasmid design and production, focusing on how these advancements can directly enhance manufacturing processes.

The webinar will highlight the latest developments in plasmid stability, yield, and purity to enhance viral vector production in CGMP environments, ensuring greater consistency and reliability. By streamlining production processes, these innovations enable seamless scale-up, making large-scale manufacturing more cost-effective and efficient. Additionally, improvements in plasmid design and production directly impact viral vector yield and efficiency, reducing manufacturing bottlenecks and accelerating cell and gene therapy development.

The speakers will highlight approaches for optimizing production processes, thereby ensuring product consistency, and reducing costs. Further, they will demonstrate how high-quality, custom plasmid solutions can contribute to the overall success of cell and gene therapies.

Attend this webinar to:

Understand the latest advancements in plasmid design that enhance the stability, yield, and purity required for viral vector production in CGMP environments.
Learn about the innovations that streamline plasmid production, making it more scalable and cost-effective for large-scale viral vector manufacturing.
Explore the importance of stringent quality control measures in plasmid production to ensure consistent, high-quality outputs for safe and effective cell and gene therapies.
Gain insights into how improved plasmid production directly impacts the efficiency and yield of viral vectors, reducing bottlenecks in the manufacturing process.

John Bowen

Senior Director, Nucleic Acids and Plasmid at SK pharmteco

John Bowen has over 10 years of experience in the biopharmaceutical industry, and is currently the Senior Director of Nucleic Acids and Plasmid Operations at SK pharmteco. He previously worked as Senior Scientist in the Viral Vector Technical Development department at Novartis Gene Therapies supporting Zolgensma and their pre-clinical viral vector pipeline. John received his Ph.D. in Chemical and Biomolecular Engineering from North Carolina State University where he focused on the screening and discovery of novel post-translationally modified peptides. Prior to his Ph.D., John worked for Merck & Co. and Novartis Vaccines supporting multiple development and commercial manufacturing programs.

Brian Tomkowicz

Vice-President, Head of R&D and Virology Fellow at

Brian is an accomplished cell and molecular biologist with 15+ years of experience in the biotech and pharmaceutical industries. His career is dedicated to the discovery, development, and delivery of curative cell and gene therapies for human diseases. Currently, he is the Senior Director, Head of Research & Development at SK pharmteco where his research focus is on cell development and viral vector engineering to improve viral vector manufacturing. Prior to SK pharmteco, he was a Senior Principal Investigator at Janssen Pharmaceuticals where he led efforts to support AAV-gene therapy preclinical development for both internal assets and external collaboration. He has a PhD in Microbiology and Molecular Virology from Thomas Jefferson University and a BS in Microbiology from Pennsylvania State University. He completed an academic post-doc at the University of Pennsylvania, under the direction of Dr. Ronald G. Collman.